Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01076335 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT01076335: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01076335 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01076335, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find out if a therapy using docetaxel chemotherapy with hormonal therapy taken before your scheduled surgery is beneficial to treatment of prostate cancer. The safety of this combination will also be studied.
Interventions
- DRUG Docetaxel
- DRUG Neoadjuvant Hormonal Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-05 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01076335
The ClinicalTrials.gov registry entry for NCT01076335 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT01076335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01076335 about?
NCT01076335 is a clinical study titled "Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer". The goal of this clinical research study is to find out if a therapy using docetaxel chemotherapy with hormonal therapy taken before your scheduled surgery is beneficial to treatment of prostate cancer. The safety of this combination will also be studied.
What is the current status of trial NCT01076335?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2005-05. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01076335?
The interventions under investigation include: Docetaxel (DRUG), Neoadjuvant Hormonal Therapy (DRUG).
Who is sponsoring clinical trial NCT01076335?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.